(Q46866899)

26 December 2017

title

Single-dose, randomized, crossover bioequivalence study of amlodipine maleate versus amlodipine besylate in healthy volunteers (English)

1 reference

26 December 2017

author name string

Fiorenzo Mignini

1

1 reference

26 December 2017

Daniele Tomassoni

2

1 reference

26 December 2017

Enea Traini

3

1 reference

26 December 2017

Francesco Amenta

4

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

Clinical and Experimental Hypertension

published in

1 reference

26 December 2017

volume

29

1 reference

26 December 2017

issue

8

1 reference

26 December 2017

page(s)

539-552

1 reference

26 December 2017

Unique pharmacologic properties of amlodipine

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Management of calcium channel antagonist overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hyp

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Use of confidence intervals in analysis of comparative bioavailability trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Power of the two one-sided tests procedure in bioequivalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Inhibition by amlodipine of activity evoked in isolated human coronary arteries by endothelin, prostaglandin F2 alpha and depolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Hypertension control in the elderly with amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

The bioequivalence of highly variable drugs and drug products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10641960701744046

10.1080/10641960701744046

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017